Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Seaport Therapeutics enters the final stretch before its November 3 earnings with the borrow market almost fully locked up and the stock nursing a 28% loss over the past month, even as every analyst covering it carries a buy rating.
The lending market tells the most striking story this week. Availability has been near zero for most of the past six weeks, running below 0.2% for long stretches through September and only recently loosening to 6.3%, still extremely tight by any measure. The 52-week low on availability was 0.05%, meaning the lending pool was essentially exhausted. Cost to borrow has climbed about 22% over the past month to nearly 8%, a meaningful increase that reflects persistent demand to short a stock with no revenue and binary clinical outcomes. Short interest itself has grown 16% over the past month in share terms, though the free-float figure is not available in this dataset, and the 30-day direction is clearly one of building pressure. The ORTEX short score is 87.8, placing Seaport in the top decile of short conviction across the universe, and it has held that elevated level with little variation for at least two weeks. Taken together, the borrow market looks about as constrained as it has been all year, with the recent slight easing in availability the only counter-signal.
The Street is uniformly bullish, which makes the short positioning all the more pointed. All six analysts covering the stock rate it a buy or better, with the consensus price target at $38.29 against a close of $17.93, implying more than 100% upside. Raymond James initiated at Strong Buy with a $46 target two weeks ago. HC Wainwright reiterated its $50 target this morning. The bull case centres on Seaport's Glyph platform, which converts existing neuropsychiatric molecules into orally delivered versions with sharply higher bioavailability, GlyphAllo showed more than nine times the oral bioavailability of native allopregnanolone, with BUOY-1 top-line data expected in the first half of 2027. Bears counter that GlyphAllo and GlyphAgo carry approval probabilities of only 60% and 40% respectively, that GlyphAgo data do not arrive until late 2028, and that the company faces the usual clinical-stage dilution risk. The price-to-book multiple has contracted about 18% over the past 30 days to 2.6 times, a reflection of the stock re-rating lower even as analyst targets stay fixed.
The ownership structure adds further context to the short-versus-analyst tension. Two shareholders, ARCH Venture Fund XII and General Atlantic, have filed Schedule 13D activist disclosures with stakes of 11.9% and 11.5% respectively, making them engaged rather than passive holders. PureTech Health, the company's parent-adjacent investor, holds 31.2% on a 13G filing. Together these three control more than half the shares. A concentrated register like this limits the free float available to borrow, which is the direct mechanical explanation for why availability has been so persistently tight: there simply are not many shares to lend when the majority are held by committed strategic investors unlikely to participate in the lending pool. Stakes are as last disclosed around the 5% threshold; any holder dropping below that level may not file again.
Retail attention has also picked up sharply. Wikipedia page views and ORTEX stock page traffic produced a combined z-score of 5.6 against the prior 90 days, an unusually high reading that suggests the stock has come onto a broader audience's radar, whether driven by the recent analyst initiations or the price decline itself.
Seaport's last three earnings reactions were a 7.4% gain, a 4.7% gain, and a 1% loss on the day, with mixed five-day follow-through. The next print lands on November 3. Between now and then, the key variables are whether the borrow market tightens again toward zero availability, whether any clinical-trial updates from the US National Library of Medicine registry move the narrative, and how the stock responds to the gap between the $38 consensus target and a price that has lost more than a quarter of its value in a month.
See the live data behind this article on ORTEX.
Open SPTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
